Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 11 of 32, showing 5 Applications out of 159 total, starting on record 51, ending on 55

# Protocol No Study Title Investigator(s) & Site(s)

51.

ECCT/24/03/07   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Prof Walter Godfrey Jaoko
Site(s) in Kenya
1. KAVI – Institute of Clinical Research (KAVI - ICR) (Nairobi City county)
 
View

52.

ECCT/23/07/03   ARNASA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Professor Videlis Nduba
2. Professor Videlis Nduba
Site(s) in Kenya
1. KENYA MEDICAL RESEARCH INSTITUTE-CENTRE FOR RESPIRATORY DISEASE RESEARCH (CRDR) (Nairobi City county)
2. KEMRI/CRDR, Siaya Clinical Research Annex (Siaya county)
3. Clinical Research Health Network (CREA-N) (Machakos county)
4. KEMRI-Mtwapa Clinical Annex (Kilifi county)
5. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
6. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
7. University of Nairobi Clinical Research Centre (Nairobi City county)
 
View

53.

ECCT/23/08/01   ARNASA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Dr Teresa Kinyari
Site(s) in Kenya
1. University of Nairobi Clinical Research Centre (Nairobi City county)
2. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
3. Clinical Research Health Network (CREA-N) (Machakos county)
4. KEMRI-CRDR Siaya Clinical Research Annex (Siaya county)
5. KEMRI-Mtwapa Clinical Annex (Kilifi county)
6. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
 
View

54.

ECCT/23/12/01   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL)   
Principal Investigator(s)
1. Prof Walter Jaoko
2. Dr. Lucas Thina Otieno
3. Prof. Kariuki Simon
4. Dr. Janet Nyawira Oyieko
5. Walter Otieno
6. Onono Dr. Marcianah
7. Dr. Lucas Thina Otieno
8. Prof. Kariuki Simon
9. Dr. Janet Nyawira Oyieko
10. Walter Otieno
11. Onono Dr. Marcianah
Site(s) in Kenya
1. KAVI-Institute of Clinical Research, University of Nairobi (Nairobi City county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
3. Walter Reed Army Institute of Research -Kericho Site (Kericho county)
4. KEMRI CCR – Butere Clinical Research Centre (Kakamega county)
5. Siaya County Referral Hospital (SCRH (Siaya county)
6. Kenya Medical Research Institute Center for Microbiology Research (CMR (Kisumu county)
7. Kombewa Clinical Research Center, KEMRI, (Kisumu county)
 
View

55.

ECCT/22/01/04   SKYSCRAPER 07
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY   
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Mansoor Saleh
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View